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Abstract
Background
Elevated blood endotoxin levels are frequently reported in the dialysis population and are
strongly linked with inflammation, a major predictor of mortality. Virtually all studies have
employed the Limulus Amoebocyte Lysate (LAL) assay to detect endotoxin. However this
assay is not endotoxin-specific and can be activated by (1!3)-β-glucan (BG), a component
of fungal cell walls leading to false positive signals. Very few studies have taken account of
this. We examined the influence of BG-based activation of the LAL assay on the detection
of endotoxemia in this setting.
Method
We measured plasma endotoxin levels in 50 hemodialysis patients with and without the
use of BG-blocking buffers. These buffers inhibit BG activation of the LAL assay to ensure
that any signal detected is endotoxin-specific. Blood samples were measured for BG, inter-
leukin-6 (IL-6), tumor necrosis factor-alfa (TNF-α) to examine the association between
endotoxin signals, BG and inflammation.
Results
Endotoxin signals were detected in 50% of patients. On repeat measurement with a BG-
blocking buffer, all detected endotoxin signals were extinguished. No patient had detect-
able endotoxemia. Plasma BG levels were significantly elevated in 58% of patients and
were higher in those with detectable endotoxin signals using the LAL assay without BG-
blocking buffers (78vs.54pg/mL;p<0.001). Endotoxin signal and BG levels did not correlate
with levels of TNF-α or IL-6.
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Conclusion
Use of the LAL assay for blood endotoxin detection in dialysis patients has its limitations
due to high blood BG. Endotoxemia frequently reported in non-infected hemodialysis
patients may be artefactual due to BG interference.
Introduction
Endotoxemia is commonly reported in the dialysis population and has been associated with
systemic inflammation[1–7]–a strong prognostic of poor outcome[8]. Endotoxins are complex
lipopolysaccharides found in the outer cell wall of gram negative bacteria. They are implicated
in the pathogenesis of sepsis syndrome and are potent mediators of inflammation. The levels of
endotoxemia reported in the dialysis population range from 0.209 to 2.31 endotoxin units/mL
(EU/mL)[2], [3], [5], [7], [9–12]. This appears high since it is well established that 4.1–5 EU/
kg/hr is sufficient to induce pyrogenic symptoms such as rigor, nausea and hypotension in
humans [13], [14]. Assuming an average 70kg patient with approximately 3L circulating
plasma volume[15], it would be expected that as little as 0.12 EU/mLwould be sufficient to
trigger pyrogenic symptoms. Reported endotoxemia in the dialysis population exceeds this
threshold.
Nearly all studies in the dialysis population have employed the use of the LAL assay to detect
endotoxin[9]. However, the LAL assay has many limitations especially when used to measure
endotoxin in complex biological substances such as plasma. LAL is a very sensitive biological
assay, capable of detecting sub-picogram/mL levels of endotoxin. The assay was originally
thought to be specific to endotoxin though it is now understood that it can also be activated by
(1!3)-β-D-glucan (BG) via an alternate enzymatic pathway mediated by factor G activation
[16]. BGs are major carbohydrate constituents of cereal, yeast and fungal cell walls[17] with a
variable molecular weight ranging from thousands to millions of daltons depending on origin
[17], [18]. The presence of elevated BG in the blood has been used as a surrogate marker of
invasive fungal infection[17]. False positive activation of LAL due to BG interference may be
partly responsible for the elevated blood endotoxin levels frequently reported in the literature.
Taniguchi et al [19] found that endotoxin levels were much lower in hemodialysis patients
when blood samples were assayed using LAL devoid of factor G compared with standard
unmodifiedLAL, although they did not measure BG levels in their study.
It is important to clarify whether blood endotoxin levels are truly raised in dialysis patients
since emerging therapies such as extracorporeal endotoxin are in development and their effi-
cacy in the treatment of sepsis syndrome has been reported [20]. These therapies could poten-
tially be applied to hemodialysis patients for treatment of chronic inflammation—a potentially
major benefit since targeted anti-inflammatory interventions are currently unavailable.
LAL assay reactivity to BG can be prevented by either using LAL reagent that lacks factor G
or by rendering the factor G component of the LAL assay unreactive to BG using BG-blocking
buffers. In a recent review of endotoxin studies in dialysis population[9], with one notable
exception[19], studies did not specify the use of LAL rendered insensitive to BG activation.
Hence it is unclear whether reported high levels of endotoxemia are truly due to endotoxin or
due to false positive interference from BG.
We recently examined the performance of a kinetic turbidimetric LAL assay in HD patients
and found that the assay was sensitive and precise for endotoxin detection in uraemic plasma
[21], [22]. Using this assay, we investigated the influence of BG on endotoxin read-out
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measurements by measuring endotoxin in HD patients with and without the use of a BG-
blocking buffer. In a separate experiment, in order to determine whether use of BG-blocking
buffers interfered with the detection of true endotoxemia, we spiked plasma samples with
known amounts of endotoxin, and measured endotoxin levels with and without the blocking
buffer. BGwas measured in plasma samples to determine its association with endotoxin.
Method
Study design
This was a single centre cross-sectional study of prevalent HD patients treated at the Lister
Renal Unit. Ethical approval was obtained from the Northampton NHS Research Ethics Com-
mittee and the study was conducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from all participants. All patients dialysed using an arterio-
venous fistula and were clinically stable at the time of study. All were treated by on-line hemo-
diafiltration using ultrapure water. Exclusion criteria were HIV infection, viral hepatitis, abnor-
mal liver function and active gastrointestinal disease.
The study was divided into two phases. The first phase compared the difference in endo-
toxin read-out measurements between standard LAL (without BG-blocking buffer [LAL(-)])
and LAL reconstituted with manufacturer supplied BG-blocking buffer (Charles Rivers1 ES-
buffer [LAL(+)]) to render the LAL insensitive to further stimulation by BG. The second phase
of the study was carried out to ensure that BG-blockingbuffers themselves do not affect the
accuracy or interfere with the sensitivity of LAL to detect endotoxin.
Phase 1: Comparison of endotoxin measurements between LAL(-) and
LAL(+)
Fifty patients were recruited. For each subject, plasma samples were assayed for endotoxin
using both LAL(-) and LAL(+). Samples were also measured for IL-6, TNF-α and BG. Correla-
tion between BG,markers of inflammation, demographic and clinical factors was explored.
Blood sampling and processing
Blood samples were collected pre-dialysis through the arterio-venous fistula using aseptic tech-
nique. Blood samples for endotoxin and BGmeasurements were collected in Terumo Venoject
II heparinised tubes (Project KBG, Tokyo). Blood samples for cytokinemeasurements were
collected in S-monovette Z-gel tubes (Sarsedt, Germany). Plasma for endotoxin and BGmea-
surements were prepared by centrifugation at 250g for 10min and serum for cytokinemeasure-
ments were prepared by centrifugation at 1500g for 10min. Plasma and serum samples were
immediately frozen and stored at -80°C. Blood collection, processing and storage were com-
pleted within 30 minutes for all samples. Phlebotomy equipment including syringes and blood
collection tubes were batch checked for endotoxin contamination[21], [23]. Washout from the
apparatus were consistently found to have undetectable endotoxin (<0.0025 EU/mL).
Laboratory measurements
Endotoxin assay using standard LALwithout BG-blocking buffer [LAL(-)]. Endotoxin
measurements were performed using the kinetic turbidimetric LAL assay (Endosafe KTA2,
Charles River Laboratories, Ecully) as previously described[21].Plasma samples were diluted
1:10 with 0.1% Tween80 (Merck Chemicals, Darmstadt) and heated to 70°C for 10min and
cooled to room temperature (20–25°C) prior to analysis. 100μL of diluted plasma was added to
duplicate wells on 96-well microplates. Endosafe KTA2 reagent was reconstituted with 5.2mL
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LAL reagent water. 100μL of this mixture was added to each sample. The plate was monitored
at 340nm using a Biotek ELx808 absorbancemicroplate reader with Endoscan-V software (ver-
sion 4.0; Charles River) with an onset optical density set at 0.03. Six-point standard curveswere
constructed using standard dilutions of control standard endotoxin (E.coli 055:B5) ranging
from 10–0.0025 EU/mL. All standard curves had a correlation coefficient>0.98. Coefficientof
variation (CV) for onset reaction times for each assay was<20%.
Endotoxin assay using LAL reconstituted with BG-blockingbuffer [LAL(+)]. To block
the factor G pathway, Endosafe KTA2 reagent was reconstituted with 5.2mL BG-blocking
buffer (Charles River ES-Buffer) containing 1mg/mL carboxymethylated curdlan[24], [25].
Endotoxin measurements were carried out using the same procedure as described above. For
each patient, samples were analysed with LAL(-) and LAL(+) simultaneously on the same
microplate. The same batch of LAL reagent was used throughout the study.
(1–3)-β-D glucan assay. BGmeasurements was carried out using the Fungitell1 assay
(Associates of Cape Cod, Inc.) as per manufacturer’s instructions[26], [27]. In brief, 5μL of
sample was mixed with 20μL pre-treatment buffer (0.125M KOH/6M KCl), in microplate
wells, and incubated at 37°C for 10min. Fungitell reagent, reconstituted in 0.1M Tris HCl, pH
7.4, was added to sample and standard curvewells (7.8–500pg/mL, Pachyman). The reactions
were read kinetically, at 405nmminus 490nm at 37°C, for 40min. Vmean values (milliabsor-
bance units/min) were calculated for standards and samples and sample titres interpolated
from the standard curve. CV for all assays was<20%. Normal human serum contains low lev-
els of BG, typically 10-40pg/mL[28]. Levels<60pg/mL are interpreted as negative and between
60-80pg/mL is interpreted as indeterminate. Levels>80pg/mL is interpreted as positive and in
at-risk patients is considered a marker of invasive fungal infection[26], [29].
Cytokinemeasurements and C-reactive protein measurements. serumwas measured
for IL-6 and TNF-α using enzyme-linked immunosorbent assays (Human Quantikine ELISA,
R&D systems). For IL-6, intra- and inter-assay CV was 1.6–4.2% and 2.0–3.7% respectively.
For TNF-α, intra- and inter-assay CV was 4.2–5.2% and 4.6–7.4% respectively. All patients at
our unit have monthly CRPmeasurements (Olympus AU2700, Beckman-Coulter) as part of
routine clinical care. Monthly CRP measurements for all patients were collected in the preced-
ing 3 months of the study to determine the chronic inflammatory status of subjects.
Measurement of BG in dialysis fluid. Dialyzers were investigated for BG contamination.
Dialysis priming fluid from 12 randomly selected dialyzers (10 Fresenius FX and 2 Gambro
Evodial dialyzers) was measured for BG as described above. The limit of detection of BG in
aqueous solutions is 7.8pg/mL.
Phase 2: Investigating the effect of BG-blocking buffers on endotoxin
spike recovery
To ensure that BG-blocking buffers themselves do not interfere with endotoxin detection, the
ability of LAL reconstituted with different doses of BG-blocking buffers to detect endotoxin
from plasma samples spiked with control standard endotoxin (lipopolysaccharide; LPS) was
explored (Fig 1).
Eight patients with undetectable endotoxemia were recruited for this sub-study. Plasma from
each subject was aliquoted and spiked with three different concentrations of LPS (0.05, 0.1 and
1EU/mL). Each spiked sample was diluted, heat-treated as described above and assayed with
LAL(-) and LAL reconstituted with different concentrations of BG-blockingbuffer. The stan-
dard inhibitor concentration of Charles River ES-buffer used to render LAL unreactive to BG
stimulation is 1mg/mL carboxymethylated curdlan[24]. Each LPS-spiked plasma sample was
assayed with LAL reconstituted with progressively diluted concentrations of carboxymethylated
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curdlan ranging from 0.01-1mg/mL to calculate percentage spike recovery. Spike recoverywas
calculated using the following formula: -
% spike recovery ¼
Measured endotoxin content in sample
Amount of endotoxin added to sample
 100%
Spike recoveries between 50–200% are considered acceptable. The wide acceptable range is
due to the fact that the LAL test is a biological assay and thus inherent variability in LAL testing
is a well-recognisedphenomenon due to differences in assay sensitivity, manufacturer reagents
and laboratory accessories [30]. The sensitivity of each lot of commercial LAL formulations
(originally gel clot formulations) is calibrated against Reference Standard Endotoxin (RSE)
supplied by the Food and Drug Administration (FDA) or the United States Pharmacopoeia
(USP). The concentration of endotoxin at which clot formation occurs is termed lambda. The
USP states that the verification of a LAL test’s proper performance (i.e. lack of interference by
the sample) is demonstrated by clot formation at ½ lambda, lambda, or twice lambda. This
requirement gave rise to the 50–200% recovery specification used to verify appropriate LAL
test performance[30], [31].
Statistical analysis
Data are presented as means and medians with respective 95% confidence intervals and inter-
quartile ranges. Paired and non-paired data were compared usingWilcoxon-signed rank and
Mann-Whitney U test respectively. Ordinal data betweenmultiple groups was compared using
Kruskal-Wallis test. Correlation was compared using Spearman’s correlation coefficient.ROC
analysis was used to identify optimum cut-off levels of BG to identify patients with detectable
endotoxemia using the LAL(-). Level of agreement between patients with detectable endotoxe-
mia and those with elevated BG levels was analysed using the kappa statistic.
Results
Patient characteristics
Patient characteristics are listed in Table 1. Mean age was 64 and median dialysis vintage was
2.8years. With the exception of one patient who dialyzed using synthetic polycarbonate hepa-
rin-grafted dialyzer (Gambro, Evodial), all were treated with synthetic polysulfone dialyzer
Fig 1. Schematic presentation of spiking experiments—plasma from each patient was aliquoted and spiked with three different
concentrations of control standard endotoxin (LPS) and each spiked sample was assayed using LAL reconstituted with different
doses of glucan blocking buffer to calculate % spike recovery. * denotes manufacturer recommended dose of glucan blocking buffer
(Charles Rivers ES-buffer ®; Endotoxin-Specific buffer) containing 1 mg/mL of carboxymethylated curdlan.
doi:10.1371/journal.pone.0164978.g001
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(Fresenius, FX high-flux).Most had evidence of inflammation, with elevated IL-6 and TNF-α.
58% of patients had evidence of chronic inflammation with median CRP>5mg/L in the three
months preceding the study.
Effect of BG-blocking buffers on plasma endotoxin detection
Using LAL(-), 50% of patients had detectable endotoxemia with median endotoxin level of
0.038EU/mL, however on repeat measurement with LAL(+), no subjects had detectable endo-
toxemia (Table 2).
Association between endotoxin signals detected using LAL(-) and (1–3)-
β-D-glucan
Apparent endotoxin signals detected using LAL(-) was higher in patients with BG levels>80pg/
mL (positive test) compared to those with BG levels<60pg/mL (negative test) [0.034 vs. 0EU/
mL; p = 0.004](Fig 2). Endotoxin signals in patients with BG levels>80pg/mL also tended to be
higher than those with BG levels between 60-80pg/mL (indeterminate result) although this did
Table 1. Patient characteristics.
Parameter Value
Age (years) 64 [95% CI, 60–69]
Male gender (%) 74
Weight (kg) 78.2 [95% CI, 73.1–83.3]
CCI 3.8 [95% CI, 3.1–4.5] 4 [IQR 2–5]
Diabetes (%) 30
Previous gastrointestinal disease (%) 14
KRU (ml/min) 0.1 [IQR 0–2.0]
Kt/V 1.44 [95% CI, 1.36–1.51]
Dialysis vintage (years) 2.8 [IQR 1.8–7.8]
Convective volume (L) 18.8 [95% CI, 16.6–23.0]
CRP (mg/L) 7.0 [IQR 5–11.3]
High CRP 5 mg/L (%) 58%
Albumin (g/L) 38.4 [95% CI, 37.4–39.4]
TNF-α (pg/mL) 13.6 [IQR 11.6–17.7]
IL-6 (pg/mL) 7.7 [IQR 4.6–14.8]
PTH (pmol/L) 38.6 [IQR 29.0–54.5]
Dialyzer surface area (m2) 1.8 [IQR 1.8–2.2]
CCI, Charlson co-morbidity index; KRU, residual urea clearance; CRP, median C-reactive protein over the
previous 3 months; PTH, parathyroid hormone; TNF-α, tumour necrosis factor-α; IL-6, interleukin-6 (values
quoted for healthy controls for IL-6 and TNF-α are <3.1pg/mL and <2.8pg/mL respectively); Kt/V, combined
dialyser and renal urea clearance normalised to body volume
doi:10.1371/journal.pone.0164978.t001
Table 2. Plasma endotoxin and (1–3)-β-D-glucan levels in patients with and without endotoxemia.
Population Plasma endotoxin (EU/mL) Plasma BG (pg/mL)
LAL(-) (No BG blocker) LAL(+) (with BG blocker)
Detectable endotoxemia (n = 25) 0.038 [IQR 0.031–0.043] Undetectable (<0.025) 78 [IQR 59–117]
No endotoxemia (n = 25) Undetectable (<0.025) Undetectable (<0.025) 54 [IQR 36–65]
p-value <0.001
doi:10.1371/journal.pone.0164978.t002
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not reach statistical significance [0.034 vs. 0.028 EU/mL; p = 0.09]. Elevated BG (>60pg/mL)
were found in 58% of patients and BG levels was significantly higher in those with detectable
endotoxemia compared to those with undetectable endotoxemia (78 vs. 54pg/mL, p<0.001
[Table 2]). These findings lend support to the notion that the ‘endotoxin’ signals detected using
LAL(-) are false positives due to interference from BG. ROC analyses revealed a strong relation-
ship between high BG levels and apparent endotoxemia using LAL(-) (AUC = 0.79 [0.66, 0.92];
p<0.001) [Fig 3]. The optimum cut-off levels for identifying patients with apparent detectable
endotoxemia were between 60-70pg/mL. BG levels>62pg/mL identified apparent endotoxemia
with sensitivity of 72% and specificity of 76%. Level of agreement between patients with appar-
ent detectable endotoxemia and those with elevated BG levels (>62pg/mL) was moderate
(kappa = 0.48, p = 0.001).
Fig 2. Endotoxin signal detected using standard LAL without BG blocking buffer displayed by
tertiles of (1–3)-β-D glucan.
doi:10.1371/journal.pone.0164978.g002
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Effect of BG-blocking buffers on endotoxin spike recovery
Endotoxin spike recovery for samples spiked with 0.05EU/mL and 0.1EU/ml was elevated at
172% and 130% respectively using LAL(-), suggesting enhancement of the LAL assay. How-
ever, this enhancement was abolished on repeat measurement with BG-blocking buffers
[LAL(+)], with spike recoveries falling closer to the expected value of 100% (106% and 97.5%
for samples spiked with 0.05EU/mL and 0.1EU/ml respectively; p<0.05)[Fig 4]. For samples
spiked with high concentrations of endotoxin (1EU/mL), spike recovery was broadly reduced
for both LAL(-) and LAL(+), with no significant differences in spike recovery. Despite this, all
spike recoveries were within industry-accepted limits of 50–200%[31] [Table 3].
Assay measurements using LAL re-constituted with increasingly dilute amounts of carboxy-
methylated curdlan resulted in progressive enhancement of spike recovery (Table 3, Fig 5).
Lower doses of BG-blocking buffer (0.01–0.1mg/mL ES buffer) caused activation of the LAL
reagent almost immediately upon reconstitution resulting in wide variability of spike recoveries
obtained using lower doses of BG-blocking buffer.
Measurement of BG in dialysis fluid
High levels of BGwere observed in a significant proportion of patients and since BG leaching
from cellulose-basedHDmembranes have been reported[32], we examined dialysers at our
unit for BG contamination. Pre- and post-dialyser saline washout from the blood compartment
of dialysers revealed very low level contamination. Post-dialyser washout tested positive for BG
Fig 3. Receiver operative curve (ROC) analysis using (1!3)-β-D glucan at cut-off level 62 pg/mL to
predict those with detectable endotoxin signals using LAL(-).
doi:10.1371/journal.pone.0164978.g003
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in 6/12 dialysers (range 8-22pg/mL).Median BG levels in post-dialyserwashout were 4.8 pg/
mL (Table 4).
Clinical correlates of (1–3)-β-D-glucan
Weight and residual urea clearance correlated negatively with plasma BG levels (r = -0.33 and
-0.31 respectively; p<0.05). Plasma BG correlated positively with endotoxin signals detected
using LAL[–] (r = 0.55, p<0.01) but did not correlate significantly with markers of inflamma-
tion including TNF-α, IL-6, albumin or CRP. There was no relationship between BG and age,
co-morbidity, dialysis vintage, dialysis adequacy as determined by Kt/V, convective volume or
dialyser surface area (Table 5).
Discussion
The levels of endotoxemia reported in the dialysis population are high and often appear close
to or to exceed the pyrogenic threshold of 4.1–5 EU/kg in humans [13], [14]. Contrary to the
high blood endotoxin levels reported in the literature, the apparent level of endotoxemia
detected using LAL(-) in our population was low with a median level of 0.038–0.041 EU/mL
Fig 4. Comparison of median spike recovery between LAL(-) and LAL(+) in plasma samples spiked
with endotoxin (box plots represent median values with interquartile range, hashed horizontal line
denotes the expected optimum spike recovery). Spike recoveries of 50–200% are considered acceptable
[31][LAL(-), standard LAL with no glucan blocking buffer; LAL(+), LAL reconstituted with Charles River® ES-
buffer containing 1mg/mL carboxymethylated curdlan].
doi:10.1371/journal.pone.0164978.g004
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[21]. These low levels do not appear to be due to sub-optimal pre-treatment of plasma to
remove inhibitory plasma components since spike recovery from all samples was sufficient and
well within the 50–200% limit (Fig 4). The plasma dilution and heat treatment conditions used
in this study was similar to those used by many other authors [33].
It is possible that the high endotoxin levels reported in the literature are due to pre-analyti-
cal factors such as contamination of phlebotomy and laboratory apparatus. Most blood collec-
tion tubes are sterile but not certified to be endotoxin-free, additives in blood collection tubes
may also be a source of contamination [9]. We paid meticulous attention to these factors by
testing phlebotomy apparatus for endotoxin contamination and interfering factors. Only man-
ufacturer-certifiedendotoxin free laboratory apparatus was used for the analysis.
False positive activation of the LAL from BGmay also be partly responsible for the appar-
ently high ‘endotoxin’ levels reported in dialysis patients. The apparent endotoxin signals
detected in 50% of our cohort using LAL(-) became undetectablewhen the assay was repeated
with LAL(+) to block factor G activation. Furthermore, endotoxin signals detected using LAL
(-) were significantly higher in those with the highest blood BG levels. These finding suggest
that endotoxin signals in this study detected using standard LAL are likely to be false positives
due to interference from BG.
The factor G pathway of LAL was inhibited using highly concentrated carboxymethylated
curdlan[25], [34]–itself a BG. The interaction between BG and factor G is complex[35]. Lower
molecular weight BG structures such as laminarin and curdlan degradation products have fac-
tor G activating properties at low concentrations, but become inhibitory at high concentra-
tions. Consistent with this, we observed an increase in endotoxin spike recovery as the
concentration of the BG-blocking buffer was progressively reduced and very dilute concentra-
tions of BG-blockingbuffer caused coagulation of the LAL reagent almost immediately upon
reconstitution. This peculiar phenomenon is the basis of commercial BG-blocking agents used
Table 3. Spike recovery from plasma samples with undetectable endotoxin using different concentrations of glucan blocking buffers. Median
spike recovery with interquartile ranges presented. Spike recoveries of 50–200% are considered acceptable [31]. Significant P values (*) indicates spike
recovery significantly different from expected % spike recovery.
Concentration of
carboxymethylated curdlan
(mg/mL)
0 1 0.5 0.1 0.01
Standard LAL (no
glucan blocking buffer)
(Manufacturer
recommended dose)
Concentration of
endotoxin spike
0.05
(Expected endotoxin
content) [EU/mL]
Spike recovery (%) 172 [108.5–210] 106 [80.5–122.5] 149 [97.5–206] 220 [134.5–343.5] 848 [271–1798]
P 0.028* 0.574 0.036* 0.012* 0.012*
Concentration of
endotoxin spike
0.1
(Expected endotoxin
content) [EU/mL]
Spike recovery (%) 130 [102.5–142.5] 97.5 [69–124] 120.5 [73.8–202.3] 160.5 [105.5–274.3] 665.5 [170.3–1391]
P 0.063 0.674 0.362 0.036* 0.012*
Concentration of
endotoxin spike
1
(Expected endotoxin
content) [EU/mL]
Spike recovery (%) 62.1 [37.6–69.5] 60.1 [46.8–67] 64.9 [44.4–85.8] 67.8 [46.2–89] 99.7 [57.8–190.5]
P 0.012* 0.012* 0.036* 0.05 0.575
doi:10.1371/journal.pone.0164978.t003
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to eliminate BG interference in LAL endotoxin detection[17] and BG-blocking agents typically
consist of solutions containing highly concentrated BG.
Highly concentrated carboxymethylated curdlan used as a BG-blocking buffer does not
appear to affect the ability of LAL to detect endotoxin[25], although previous studies have
Fig 5. Comparison of median spike recovery between LAL and LAL reconstituted with different doses of BG blocking
buffer (ES buffer). Spike recoveries of 50–200% are considered acceptable [31] [box plots represent median spike recovery
with interquartile range, hashed horizontal line denotes the expected optimum spike recovery].
doi:10.1371/journal.pone.0164978.g005
Table 4. BG measurements of saline washout pre- and post-dialyzer.
Pre-dialyzer (n = 12) Post-dialyzer (n = 12) P
(1–3)-β-D-glucan (pg/mL) Below detection limit 4.8 [IQR 0–9.8] 0.046*
Limit of detection was 7.8pg/mL, values <7.8pg/ml was designated as 0
*denotes statistical significance P<0.05
doi:10.1371/journal.pone.0164978.t004
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tested this in plasma samples spiked with relatively high concentrations of LPS. Since endo-
toxin content in our patients with detectable endotoxemia was relatively low (median
0.038EU/ml), to ensure that the BG-blocking buffer used in this study did not interfere with
true endotoxin detection at this level of endotoxemia, we examined the effect of the BG-block-
ing buffer on the LAL assay’s ability to recover endotoxin from plasma spiked with lower
amounts of endotoxin (0.05–0.1EU/mL). Spike recovery was enhanced (130–172%) using
LAL(-), however on repeat measurement using LAL(+), this enhancement was abolished with
spike recoveries falling closer to expected values (97.5–106%). This suggests that within this
range of endotoxemia, there could be enhancement of the LAL assay by BG present in the
blood, supporting the hypothesis that ‘endotoxemia’ detected in HD patients may be artefac-
tual due to BG interference. This also demonstrates that BG-blocking buffers used in this study
do not interfere with the sensitivity of the LAL assay to detect endotoxin since spike recovery
using LAL(+) was close to 100%. All spike recoveries obtained were within the industry-speci-
fied limits of 50–200%. As the LAL test is a biological assay and is subject to inherent variabil-
ity, wide-ranging spike recoveries are permitted[31], therefore this may lead to LAL users
accepting results of endotoxin measurement and not taking steps to rule out BG positive
interference.
In samples spiked with a high concentration of endotoxin (1EU/mL), spike recovery was
broadly reduced and there was no significant difference in spike recovery between LAL(-) and
LAL(+), possibly reflecting that the contribution of residual BG signal was only a small propor-
tion of the overall signal when higher concentration of LPS is used. Overall spike recovery was
broadly reduced compared to samples spiked with smaller amounts of LPS, We are unable to
explain this observation although improvement of endotoxin recovery from plasma using
detergent have been reported[21], [36], [37] and since detergents alter the aggregative state of
endotoxin in high protein content solutions[38], this suggests that the structure and potency of
Table 5. Clinical correlates of (1–3)-β-D glucan, endotoxin signals detected using LAL[–] and markers of inflammation.
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13
1 BG
2 Endotoxin LAL[–] 0.55**
3 IL-6 -0.11 0.16
4 TNF-α -0.01 0.01 0.17
5 CRP -0.16 0.18 0.53** 0.05
6 Albumin -0.03 -0.14 -0.2 -0.33* -0.08
7 Age 0.09 0.14 0.2 0.01 -0.09 -0.32*
8 Weight -0.33* -0.37** 0.21 0.02 0.21 0.05 -0.15
9 KRU -0.31* -0.11 0.06 -0.13 0.13 0.13 0 0.47**
10 CCI -0.12 0 0.30* 0.19 0.01 -0.47** 0.76** -0.08 0.01
11 Dialysis vintage 0.14 0.17 0.01 0.32* -0.03 -0.21 0.15 -0.3* -0.54** 0.28
12 Kt/V 0.08 0.2 -0.07 -0.16 -0.07 -0.03 0.33* -0.15 0.33* 0.23 -0.21
13 Convective volume 0.02 -0.22 -0.16 -0.16 0.04 0.15 -0.28 0.26 -0.23 -0.32* 0.12 -0.21
14 Dialyser surface area -0.2 -0.24 0.28 -0.01 0.35* -0.11 -0.07 0.73** 0.19 0.01 -0.06 -0.15 0.27
*p<0.05
**p<0.01
BG, (1–3)-β-D glucan; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; CRP, median C-reactive protein over the previous 3 months; KRU, residual urea
clearance; CCI, Charlson Co-morbidity index; Kt/V, combined dialyser and renal urea clearance normalised to body volume; Endotoxin LAL[–], Endotoxin
signals detected using LAL assay without BG-blocking buffers
doi:10.1371/journal.pone.0164978.t005
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endotoxin moleculesmay be altered when a large amount of endotoxin is spiked directly in
plasma.
Elevated levels of blood BGwere found in a large proportion of patients. The clinical signifi-
cance of high blood BG levels in-vivo is unclear. There was no relationship between BGwith
markers of inflammation in this study although only two pro-inflammatory cytokines were
studied. A broader inflammatory profile may have been useful as BG has been shown to stimu-
late release of a number of other pro-inflammatory cytokines such as IL-8 [39], [40]. Different
cut-off levels of BG are used as a diagnosticmarker in invasive fungal infections and in-vitro
evidence suggests that BGmay potentiate enhanced Toll-like receptor-induced cytokine pro-
duction[41]. However, the use of BG as adjunctive therapies for treatment of malignancies has
been reported [17], [18], [42], [43]. The source of high BG in our study is unknown. Though
we found no evidence in single-pass experiments that the dialysis membranes were involved in
significant BG generation, we cannot discount the possibility that cumulative treatments over
many years may increase BG levels, however there was no correlation between BG levels and
dialysis vintage. The gut is a potential source of high BG levels given reports of translocation of
intestinal luminal contents due to disturbed gut permeability in uraemia[44–46], although we
did not observe a relationship between BG levels and history of gastrointestinal disease.We
found an inverse relationship between BGwith weight and residual kidney function. Animal
studies suggest that BG are cleared mainly by the liver[47], [48] and degraded oxidatively in
the reticuloendothelial system[17], [49], with minimal excretion by the kidney. The role of kid-
ney function in BG excretion is poorly understood[47] and requires further investigation.
The strengths of this study include the use of a kinetic turbidimetric LAL assay which we
found to have good performance for endotoxin detection in uraemia[21], [22]. Meticulous pre-
cautions were taken to minimise risk of environmental contamination of plasma samples from
phlebotomy and laboratory apparatus. Plasma samples were examined for BG using a detection
assay which has been extensively validated as a diagnostic adjunct of invasive fungal infections
and cleared for marketing by the FDA[26]. Due to the inherent variable nature of LAL testing
[30], measures were taken to minimize inter-batch and inter-plate variation by conducting the
analysis using the same batch of LAL and conducting assay measurements on the same micro-
plate for each subject. The limitations include the relatively small sample size and the use of
reagents from only one manufacturer. It is unclear whether a similar conclusion would be
reached if LAL reagents and BG-blocking buffers from other manufacturers were used. How-
ever, a previous study similarly found a low prevalence of detectable endotoxemia in HD
patients whenmeasurements were carried out using LAL devoid of factor G[19]. Finally, endo-
toxin used for spiking experiments should ideally have been conducted using natural endotoxin
rather than control standard endotoxin (LPS) for assessment of spike recovery, however natu-
ral endotoxin is difficult to standardise which precluded its use in this study.
In conclusion, BG presence represents a significant limitation with the LAL assay for endo-
toxin detection in dialysis patients. Our data demonstrate that endotoxin measurement, in a
setting free of BG contribution from dialyzer equipment or dialysis fluids, suffers from signifi-
cant, positive BG interference, especially at very low levels of reported endotoxin. Accordingly,
endotoxin measurements in dialysis patients should be carried out with LAL rendered insensi-
tive to BG. Raised BG levels were found in a significant proportion of HD patients. The source
and clinical significance of this is unknown and warrants additional study.
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